STO · GENO.ST
Genovis AB
SEK 21.80-SEK 0.20 (-0.91%)
Genovis AB’s quoted price sits in the upper half of its reported 52-week range, 7.82% below the high.
Loading market information…
STO · ITECH.ST · SEK
Stock price, dividends, earnings
Quote as of Oct 29, 2026, 04:29 PM UTC. Cached market data; not a live quote.
One-year closing-price history · SEK. Historical prices are not a forecast.
I-Tech AB’s quoted price sits in the lower half of its reported 52-week range, 27.35% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
BEHIND THE RESULTS
I-Tech AB’s next earnings report is currently expected on Feb 4, 2027, with estimated earnings per share of SEK 0.93. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow I-Tech AB’s reporting calendar.
THE COMPANY BEHIND THE TICKER
I-Tech AB, a biotechnology firm established in Mölndal, Sweden, in 2000, focuses on creating and commercializing products to prevent biofouling. Their flagship innovation is Selektope, a unique bio-repellent ingredient engineered for marine coatings. This compound provides crucial protection against hard fouling on ships, primarily by temporarily stimulating the swimming behavior of barnacle larvae, thereby preventing them from attaching to coated surfaces. The company's primary clientele is the marine coatings industry.
Latest available per-share figures in SEK. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 01:22 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q2 2025 | Aug 22, 2025 | SEK 0.39-72.14% vs estimate | SEK 32.00M-38.46% vs estimate |
|---|
| Q1 2025 | May 8, 2025 | SEK 1.20-14.29% vs estimate | SEK 57.00M+10.68% vs estimate |
|---|
| Q4 2024 | Feb 6, 2025 | SEK 1.20+33.33% vs estimate | SEK 58.00M+38.1% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
SEK 21.80-SEK 0.20 (-0.91%)
Genovis AB’s quoted price sits in the upper half of its reported 52-week range, 7.82% below the high.
SEK 16.76-SEK 0.72 (-4.12%)
SynAct Pharma AB’s quoted price sits in the upper half of its reported 52-week range, 31.87% below the high.
SEK 68.30+SEK 0.40 (+0.59%)
Infant Bacterial Therapeutics AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 19.55% below the high.
SEK 9.22+SEK 0.23 (+2.56%)
Sedana Medical AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 33.76% below the high.
SEK 23.20+SEK 1.70 (+7.91%)
C-Rad AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 41.12% below the high.
SEK 1.71+SEK 0.05 (+3.07%)
Oncopeptides AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 72.13% below the high.
SEK 10.70+SEK 0.22 (+2.1%)
Xspray Pharma AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 70.4% below the high.
SEK 1.67+SEK 0.20 (+13.2%)
Cantargia AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 74.63% below the high.
